1. Home
  2. LUCY vs PMCB Comparison

LUCY vs PMCB Comparison

Compare LUCY & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Eyewear Inc.

LUCY

Innovative Eyewear Inc.

HOLD

Current Price

$0.95

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.44

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUCY
PMCB
Founded
2017
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7M
6.3M
IPO Year
2021
2001

Fundamental Metrics

Financial Performance
Metric
LUCY
PMCB
Price
$0.95
$0.44
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 510.2K
302.6K
Earning Date
05-14-2026
03-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 63.39
N/A
EPS
N/A
★ N/A
Revenue
★ $2,661,669.00
N/A
Revenue This Year
$175.92
N/A
Revenue Next Year
$205.56
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 62.65
N/A
52 Week Low
$0.65
$0.33
52 Week High
$2.08
$1.51

Technical Indicators

Market Signals
Indicator
LUCY
PMCB
Relative Strength Index (RSI) 57.04 44.03
Support Level $0.90 $0.33
Resistance Level $0.97 $0.77
Average True Range (ATR) 0.05 0.05
MACD 0.00 0.01
Stochastic Oscillator 85.29 63.10

Price Performance

Historical Comparison
LUCY
PMCB

About LUCY Innovative Eyewear Inc.

Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.

Share on Social Networks: